Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Merck
Mallinckrodt
McKinsey
Boehringer Ingelheim

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

UROXATRAL Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Uroxatral, and when can generic versions of Uroxatral launch?

Uroxatral is a drug marketed by Concordia and is included in one NDA.

The generic ingredient in UROXATRAL is alfuzosin hydrochloride. There are nineteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the alfuzosin hydrochloride profile page.

Drug patent expirations by year for UROXATRAL
Drug Prices for UROXATRAL

See drug prices for UROXATRAL

Drug Sales Revenue Trends for UROXATRAL

See drug sales revenues for UROXATRAL

Recent Clinical Trials for UROXATRAL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
SanofiN/A
University Hospitals Cleveland Medical CenterN/A
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Phase 3

See all UROXATRAL clinical trials

Recent Litigation for UROXATRAL

Identify potential future generic entrants

District Court Litigation
Case NameDate
Sanofi-Aventis v. Apotex Inc.2008-06-23
In re: Alfuzosin Hydrochloride Patent Litigation2008-06-09
Sanofi-Aventis v. Wockhardt Limited2008-03-14

See all UROXATRAL litigation

Pharmacology for UROXATRAL
Synonyms for UROXATRAL
(+-)-N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furamide monohydrochloride
(methyl)amino)propyl)tetrahydrofuran-2
133880-44-1
2-Furancarboxamide, N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-, monohydrochloride (+-)-
4-Amino-6,7-dimethoxy-2-[methyl[3-[(tetrahydro-2-furoyl)amino]propyl]amino]quinazoline Hydrochloride
403A681
81403-68-1
81403-80-7 (Parent)
A2591
AB0008072
AB2000094
AC-1116
AC1L2GRP
AC1Q5PED
AKOS015966770
Alfetim
Alfoten
Alfuzosin (hydrochloride)
Alfuzosin for peak identification, European Pharmacopoeia (EP) Reference Standard
Alfuzosin for system suitability A, European Pharmacopoeia (EP) Reference Standard
Alfuzosin for system suitability, European Pharmacopoeia (EP) Reference Standard
Alfuzosin HCl
Alfuzosin Hydrochloride
Alfuzosin hydrochloride (JAN/USAN)
Alfuzosin hydrochloride (Uroxatral)
Alfuzosin hydrochloride [USAN:USP]
Alfuzosin hydrochloride [USAN]
Alfuzosin hydrochloride, >=98% (HPLC), solid
Alfuzosin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Alfuzosin hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Alfuzosin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Alfuzosin Hydrochloride,(S)
Alfuzosin hydrochloride;
API0001407
AS-14240
AT-12271
BC677639
BCP9000271
BCPP000417
C19H27N5O4
C19H28ClN5O4
CAS-81403-68-1
CC-23835
CCG-213373
CHEBI:32286
CHEMBL1723
CS-2087
CTK8F7637
D01692
DSSTox_CID_25514
DSSTox_GSID_45514
DSSTox_RID_80924
DTXSID3045514
FT-0630890
HMS1569A05
HY-B0192A
K448
KS-00000XK8
LP00224
LS-70107
MFCD00879135
MolPort-006-391-851
N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide hydrochloride
N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)
N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)propyl)tetrahydrofuran-2-carboxamide hydrochloride
N-[3-[(4-Amino-6,7-dimethoxy-2-quinazolinyl)(methyl)amino]propyl]tetrahydro-2-furancarboxamide Hydrochloride
n-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide hydrochloride
N-[3-[(4-Amino-6,7-dimethoxy-2-quinazolynyl)methylamino]propyl]tetrahydro-2-furancarboxamide hydrochloride
N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide hydrochloride
N-[3-[4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide hydrochloride
n-{3-[(4-amino-6,7-dimethoxychinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamidhydrochlorid
NCGC00016946-01
NCGC00095152-09
NCGC00260909-01
s1409
SCHEMBL179910
SL 77 499-10
SL 77499-10
SL-77.0499-10
SL-77499
SL-77499-10
SL-7749910
SL77.0499-10
SR-01000759345
SR-01000759345-5
SW196913-4
Tox21_110701
Tox21_110701_1
Tox21_500224
Urion
Uroxatral (TN)
Uroxatral hydrochloride
Xatral
Xatral OD
Xatral Retard
Xatral SR
Xatral XL
YTNKWDJILNVLGX-UHFFFAOYSA-N

US Patents and Regulatory Information for UROXATRAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia UROXATRAL alfuzosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021287-001 Jun 12, 2003 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for UROXATRAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia UROXATRAL alfuzosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021287-001 Jun 12, 2003   Start Trial   Start Trial
Concordia UROXATRAL alfuzosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021287-001 Jun 12, 2003   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for UROXATRAL
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 10 mg ➤ Subscribe   Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Dow
AstraZeneca
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.